Significant Therapeutic Efficacy With Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer

Journal of Nuclear Medicine - China
doi 10.2967/jnumed.115.157362
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Society of Nuclear Medicine

Related search

LY3009120, a panRAF Inhibitor, Has Significant Anti-Tumor Activity in BRAF and KRAS Mutant Preclinical Models of Colorectal Cancer

Oncotarget
Oncology
2016English

PTEN Loss of Expression Predicts Cetuximab Efficacy in Metastatic Colorectal Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2007English

PTEN Status in Advanced Colorectal Cancer Treated With Cetuximab

British Journal of Cancer
Cancer ResearchOncology
2009English

CXCR2 Inhibition Combined With Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer

PLoS ONE
Multidisciplinary
2015English

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination With Trametinib in KRAS-mutant Pancreatic and Colorectal Cancer

Cancer Research
Cancer ResearchOncology
2019English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Mechanism of Resistance to Cetuximab Therapy in Colorectal Cancer

mAbs
AllergyImmunology
2012English

Dual Promoter-Controlled Oncolytic Adenovirus CG5757 Has Strong Tumor Selectivity and Significant Antitumor Efficacy in Preclinical Models

Clinical Cancer Research
Cancer ResearchOncology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy